These include therapies directed against the epidermal growth factor (EGF) receptor and human epidermal growth factor receptor (HER)-2 for lung and breast cancers, B-RAF protein inhibitors in melanoma, estrogen targeted therapies in breast cancer and VEGF/VEGFR targeted therapies in prostate cancer (reviewed in [30]). The gene discussed is ERBB2; the disease is breast cancer.